Patents by Inventor Svetlana O. Doronina

Svetlana O. Doronina has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS
    Publication number: 20140220047
    Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Application
    Filed: February 28, 2014
    Publication date: August 7, 2014
    Applicant: Seattle Genetics, Inc.
    Inventors: Svetlana O. Doronina, Peter D. Senter, Brian E. Toki, Toni Beth Kline
  • HUMANIZED ANTI-CD40 ANTIBODIES
    Publication number: 20140193405
    Abstract: Provided are humanized anti-CD40 antibodies and antigen-binding fragments and methods for treating disease characterized by expression of CD40 antigen.
    Type: Application
    Filed: March 10, 2014
    Publication date: July 10, 2014
    Applicants: Seattle Genetics, Inc., Genentech, Inc.
    Inventors: Leonard G. Presta, Lori Y. O'Connell, Svetlana O. Doronina
  • Monomethylvaline compounds capable of conjugation to ligands
    Patent number: 8703714
    Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Grant
    Filed: April 29, 2011
    Date of Patent: April 22, 2014
    Assignee: Seattle Genetics, Inc.
    Inventors: Svetlana O. Doronina, Peter D. Senter, Brian E. Toki, Toni Beth Kline
  • HUMANIZED ANTI-CD40 ANTIBODIES CONJUGATED TO THERAPEUTIC AGENTS
    Publication number: 20130315900
    Abstract: Provided are humanized anti-CD40 antibodies and antigen-binding fragments and methods for treating disease characterized by expression of CD40 antigen.
    Type: Application
    Filed: June 25, 2013
    Publication date: November 28, 2013
    Applicants: Seattle Genetics, Inc., Genentech, Inc.
    Inventors: Leonard G. Presta, Lori Y. O'Connell, Svetlana O. Doronina
  • Monomethylvaline compounds capable of conjugation to ligands
    Patent number: 8557780
    Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Grant
    Filed: April 29, 2011
    Date of Patent: October 15, 2013
    Assignee: Seattle Genetics, Inc.
    Inventors: Svetlana O. Doronina, Peter D. Senter, Brian E. Toki
  • Methods of treating drug-resistant cancers
    Patent number: 8512707
    Abstract: Methods of treating a refractory or drug resistant cancer, cell proliferative disorder and tumor cells are provided.
    Type: Grant
    Filed: April 19, 2010
    Date of Patent: August 20, 2013
    Assignee: Seattle Genetics, Inc.
    Inventors: Svetlana O. Doronina, Charles G. Cerveny, Alan F. Wahl
  • Monomethylvaline compounds having phenylalanine side-chain replacements at the C-terminus
    Patent number: 8343928
    Abstract: Auristatin peptide analogs of MeVal-Val-Dil-Dap-Phe (MMAF) are provided having C-terminal phenylalanine residue side chain replacements or modifications which are provided alone or attached to ligands through various linkers. The related conjugates can target specific cell types to provide therapeutic benefit.
    Type: Grant
    Filed: July 7, 2006
    Date of Patent: January 1, 2013
    Assignee: Seattle Genetics, Inc.
    Inventors: Svetlana O. Doronina, Toni Beth Kline
  • Humanized anti-CD40 antibodies and their methods of use
    Patent number: 8303955
    Abstract: Provided are humanized anti-CD40 antibodies and antigen-binding fragments and methods for treating disease characterized by expression of CD40 antigen.
    Type: Grant
    Filed: May 26, 2006
    Date of Patent: November 6, 2012
    Assignee: Seattle Genetics, Inc.
    Inventors: Leonard G. Presta, Lori Y. O'Connell, Svetlana O. Doronina
  • Auristatins having an aminobenzoic acid unit at the N terminus
    Patent number: 8288352
    Abstract: Auristatin-type peptides are disclosed which are highly cytotoxic, synthetically accessible, and can be conjugated to antibodies and other ligands.
    Type: Grant
    Filed: November 14, 2005
    Date of Patent: October 16, 2012
    Assignee: Seattle Genetics, Inc.
    Inventors: Svetlana O. Doronina, Brian A. Mendelsohn
  • MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS
    Publication number: 20120148608
    Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Application
    Filed: February 15, 2012
    Publication date: June 14, 2012
    Applicant: Seattle Genetics, Inc.
    Inventors: Svetlana O. Doronina, Peter D. Senter, Brian E. Toki, Allen J. Ebens, Toni Beth Kline, Paul Polakis, Mark X. Sliwkowski, Susan D. Spencer
  • MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS
    Publication number: 20120148610
    Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Application
    Filed: February 15, 2012
    Publication date: June 14, 2012
    Applicant: Seattle Genetics, Inc.
    Inventors: Svetlana O. Doronina, Peter D. Senter, Brian E. Toki, Allen J. Ebens, Toni Beth Kline, Paul Polakis, Mark X. Sliwkowski, Susan D. Spencer
  • MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS
    Publication number: 20120141510
    Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Application
    Filed: February 15, 2012
    Publication date: June 7, 2012
    Applicant: SEATTLE GENETICS, INC.
    Inventors: Svetlana O. Doronina, Peter D. Senter, Brian E. Toki, Allen J. Ebens, Toni Beth Kline, Paul Polakis, Mark X. Sliwkowski, Susan D. Spencer
  • MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS
    Publication number: 20120141508
    Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Application
    Filed: February 15, 2012
    Publication date: June 7, 2012
    Applicant: Seattle Genetics, Inc.
    Inventors: Svetlana O. Doronina, Peter D. Senter, Brian E. Toki, Allen J. Ebens, Toni Beth Kline, Paul Polakis, Mark X. Sliwkowski, Susan D. Spencer
  • MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS
    Publication number: 20120141509
    Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Application
    Filed: February 15, 2012
    Publication date: June 7, 2012
    Applicant: Seattle Genetics, Inc.
    Inventors: Svetlana O. Doronina, Peter D. Senter, Brian E. Toki, Allen J. Ebens, Toni Beth Kline, Paul Polakis, Mark X. Sliwkowski, Susan D. Spencer
  • MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS
    Publication number: 20120034246
    Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Application
    Filed: April 19, 2011
    Publication date: February 9, 2012
    Applicant: SEATTLE GENETICS, INC.
    Inventors: SVETLANA O. DORONINA, PETER D. SENTER, BRIAN E. TOKI, ALLEN J. EBENS, TONI BETH KLINE, PAUL POLAKIS, MARK X. SLIWKOWSKI, SUSAN D. SPENCER
  • MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS
    Publication number: 20120034247
    Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Application
    Filed: July 22, 2011
    Publication date: February 9, 2012
    Applicant: Seattle Genetics, Inc.
    Inventors: Svetlana O. Doronina, Peter D. Senter, Brian E. Toki, Allen J. Ebens, Toni Beth Kline, Paul Polakis, Mark X. Sliwkowski, Susan D. Spencer
  • MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS
    Publication number: 20120027784
    Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Application
    Filed: July 22, 2011
    Publication date: February 2, 2012
    Applicant: Seattle Genetics, Inc.
    Inventors: Svetlana O. Doronina, Peter D. Senter, Brian E. Toki, Allen J. Ebens, Toni Beth Kline, Paul Polakis, Mark X. Sliwkowski, Susan D. Spencer
  • MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS
    Publication number: 20120027783
    Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Application
    Filed: July 22, 2011
    Publication date: February 2, 2012
    Applicant: Seattle Genetics, Inc.
    Inventors: SVETLANA O. DORONINA, PETER D. SENTER, BRIAN E. TOKI, ALLEN J. EBENS, TONI BETH KLINE, PAUL POLAKIS, MARK X. SLIWKOWSKI, SUSAN D. SPENCER
  • MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS
    Publication number: 20120003248
    Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Application
    Filed: April 29, 2011
    Publication date: January 5, 2012
    Applicant: Seattle Genetics, Inc.
    Inventors: Svetlana O. Doronina, Peter D. Senter, Brian E. Toki, Allen J. Ebens, Toni Beth Kline, Paul Polakis, Mark X. Sliwkowski, Susan D. Spencer
  • MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS
    Publication number: 20120003247
    Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Application
    Filed: April 29, 2011
    Publication date: January 5, 2012
    Applicant: Seattle Genetics, Inc.
    Inventors: Svetlana O. Doronina, Peter D. Senter, Brian E. Toki